<DOC>
	<DOCNO>NCT01272258</DOCNO>
	<brief_summary>PRO 140 2102 phase 2b , national , multicenter , randomize , double-blind , placebo-controlled study order evaluate safety efficacy PRO 140 ( anti-CCR5 monoclonal antibody ) administer subcutaneously adjunct new , optimize , oral antiretroviral regimen HIV-infected injection drug user viral rebound document poor adherence previous antiretroviral regimen .</brief_summary>
	<brief_title>A Trial Observed Long-acting , Anti-HIV Treatment With Monoclonal CCR5 Antibody ( PRO 140 ) Adjunct New , Optimized , Oral Antiretroviral Regimen HIV-infected Injection Drug Users With Viral Rebound Documented Poor Adherence</brief_title>
	<detailed_description />
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>HIV Antibodies</mesh_term>
	<mesh_term>PRO-140 monoclonal antibody</mesh_term>
	<criteria>Key 1 . Only R5 virus 2 . HIV1 RNA &gt; 1,000 copies/mL &lt; 100,000 copies/mL 3 . CD4+ lymphocyte count &gt; 100 cells/Î¼L 4 . Nonprescription recreational drug use within previous 6 month Key 1 . Females pregnant ( positive blood test ) , lactate , breastfeed , plan become pregnant study 2 . Prior use CCR5 entry inhibitor 3 . History acquire immune deficiency syndrome ( AIDS ) define illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>